文献速递心脑血管急症

基因型指导口服P2Y12抑制剂选择与常规氯吡格雷治疗对经皮冠状动脉介入治疗后缺血结局的影响:TAILOR-PCI随机临床试验

Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial.
PubMed 文献 · JAMA · 2020-01-01
一句话结论在CYP2C19功能缺失携带者中,基因型指导选择P2Y12抑制剂对比常规氯吡格雷,12个月主要复合缺血终点无统计学显著差异(HR 0.66,95%CI 0.43-1.02,P=.06)。

TAILOR-PCI为开放标签随机临床试验,纳入5302例因急性冠脉综合征或稳定冠心病行经皮冠状动脉介入治疗的患者,来自美国、加拿大、韩国和墨西哥40个中心,2013年5月至2018年10月入组。基因型指导组(n=2652)床旁基因分型,CYP2C19功能缺失携带者用替格瑞洛、非携带者用氯吡格雷;常规组(n=2650)用氯吡格雷,12个月后基因分型。在1849例CYP2C19功能缺失携带者中,基因型指导组主要终点(心血管死亡、心肌梗死、卒中、支架血栓和严重复发性缺血复合终点)12个月发生率为4.0%(35/903),常规组为5.9%(54/946),HR 0.66(95%CI 0.43-1.02),P=.06。全部随机患者中主要终点基因型指导组4.4%(113/2641)vs 常规组5.3%(135/2635),HR 0.84(95%CI 0.65-1.07),P=.16。11个预设次要终点均无显著差异。

要点

  • 在CYP2C19功能缺失携带者中,基因型指导组12个月主要复合缺血终点4.0%(35/903)vs 常规组5.9%(54/946),HR 0.66(95%CI 0.43-1.02),P=.06,未达统计学显著。
  • 全部随机患者中主要终点基因型指导组4.4%(113/2641)vs 常规组5.3%(135/2635),HR 0.84(95%CI 0.65-1.07),P=.16,无显著差异。
  • CYP2C19功能缺失携带者中,大或小出血12个月基因型指导组1.9% vs 常规组1.6%,HR 1.22(95%CI 0.60-2.51),P=.58。
  • 11个预设次要终点均未显示显著差异。
  • 该试验在预设分析计划和所把握检测的治疗效应下,未证明基因型指导策略优于常规氯吡格雷。

适用人群与场景

  • 因急性冠脉综合征或稳定冠心病行经皮冠状动脉介入治疗的患者,来自美国、加拿大、韩国和墨西哥40个中心,2013年5月至2018年10月入组,最终随访日期2019年10月。
  • 随机患者中82%为急性冠脉综合征,18%为稳定冠心病;中位年龄62岁,25%为女性。

处置流程与药物剂量

  • 基因型指导组(n=2652)行床旁基因分型,CYP2C19功能缺失携带者处方替格瑞洛,非携带者处方氯吡格雷。
  • 常规组(n=2650)处方氯吡格雷,并在12个月后行基因分型。
  • CYP2C19功能缺失携带者中,基因型指导组85%(764/903)接受替格瑞洛,常规组99%(932/946)接受氯吡格雷。

研究设计与关键结果

  • 开放标签随机临床试验,5302例患者随机,来自40个中心,82%为急性冠脉综合征、18%为稳定冠心病,94%完成试验。
  • 主要终点为12个月心血管死亡、心肌梗死、卒中、支架血栓和严重复发性缺血的复合终点;在CYP2C19功能缺失携带者中,基因型指导组4.0%(35/903)vs 常规组5.9%(54/946),HR 0.66(95%CI 0.43-1.02),P=.06。
  • 全部随机患者中主要终点基因型指导组4.4%(113/2641)vs 常规组5.3%(135/2635),HR 0.84(95%CI 0.65-1.07),P=.16。
  • 次要终点大或小出血在CYP2C19功能缺失携带者中基因型指导组1.9% vs 常规组1.6%,HR 1.22(95%CI 0.60-2.51),P=.58。
  • 11个预设次要终点均未显示显著差异。
  • 试验把握度85%,检测最小风险比0.50。

证据类型、等级与局限

  • 证据类型:开放标签随机临床试验(TAILOR-PCI),ClinicalTrials.gov注册号NCT01742117。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在CYP2C19功能缺失携带者中,基因型指导选择口服P2Y12抑制剂对比常规氯吡格雷,基于预设分析计划和试验所把握检测的治疗效应,12个月主要复合缺血终点无统计学显著差异。
  • 全部随机患者中主要终点亦无统计学显著差异(HR 0.84,95%CI 0.65-1.07,P=.16)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: After percutaneous coronary intervention (PCI), patients with CYP2C19*2 or *3 loss-of-function (LOF) variants treated with clopidogrel have increased risk of ischemic events. Whether genotype-guided selection of oral P2Y12 inhibitor therapy improves ischemic outcomes is unknown.

OBJECTIVE: To determine the effect of a genotype-guided oral P2Y12 inhibitor strategy on ischemic outcomes in CYP2C19 LOF carriers after PCI.

DESIGN, SETTING, AND PARTICIPANTS: Open-label randomized clinical trial of 5302 patients undergoing PCI for acute coronary syndromes (ACS) or stable coronary artery disease (CAD). Patients were enrolled at 40 centers in the US, Canada, South Korea, and Mexico from May 2013 through October 2018; final date of follow-up was October 2019.

INTERVENTIONS: Patients randomized to the genotype-guided group (n = 2652) underwent point-of-care genotyping. CYP2C19 LOF carriers were prescribed ticagrelor and noncarriers clopidogrel. Patients randomized to the conventional group (n = 2650) were prescribed clopidogrel and underwent genotyping after 12 months.

MAIN OUTCOMES AND MEASURES: The primary end point was a composite of cardiovascular death, myocardial infarction, stroke, stent thrombosis, and severe recurrent ischemia at 12 months. A secondary end point was major or minor bleeding at 12 months. The primary analysis was in patients with CYP2C19 LOF variants, and secondary analysis included all randomized patients. The trial had 85% power to detect a minimum hazard ratio of 0.50.

RESULTS: Among 5302 patients randomized (median age, 62 years; 25% women), 82% had ACS and 18% had stable CAD; 94% completed the trial. Of 1849 with CYP2C19 LOF variants, 764 of 903 (85%) assigned to genotype-guided therapy received ticagrelor, and 932 of 946 (99%) assigned to conventional therapy received clopidogrel. The primary end point occurred in 35 of 903 CYP2C19 LOF carriers (4.0%) in the genotype-guided therapy group and 54 of 946 (5.9%) in the conventional therapy group at 12 months (hazard ratio [HR], 0.66 [95% CI, 0.43-1.02]; P = .06). None of the 11 prespecified secondary end points showed significant differences, including major or minor bleeding in CYP2C19 LOF carriers in the genotype-guided group (1.9%) vs the conventional therapy group (1.6%) at 12 months (HR, 1.22 [95% CI, 0.60-2.51]; P = .58). Among all randomized patients, the primary end point occurred in 113 of 2641 (4.4%) in the genotype-guided group and 135 of 2635 (5.3%) in the conventional group (HR, 0.84 [95% CI, 0.65-1.07]; P = .16).

CONCLUSIONS AND RELEVANCE: Among CYP2C19 LOF carriers with ACS and stable CAD undergoing PCI, genotype-guided selection of an oral P2Y12 inhibitor, compared with conventional clopidogrel therapy without point-of-care genotyping, resulted in no statistically significant difference in a composite end point of cardiovascular death, myocardial infarction, stroke, stent thrombosis, and severe recurrent ischemia based on the prespecified analysis plan and the treatment effect that the study was powered to detect at 12 months.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01742117.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Pereira NL, Farkouh ME, So D, et al. Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial. JAMA. 2020. PMID: 32840598. doi:10.1001/jama.2020.12443

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。